{"relation": [["", "Group 1: H1N1+Placebo; H1N1+Placebo; TIV", "Group 2: H1N1+TIV; H1N1+Placebo; Placebo", "Group 3: H1N1+Placebo; H1N1+TIV; Placebo", "Group 4: TIV+Placebo; H1N1+Placebo; H1N1", "Total"], ["Description", "Participants received 15 mcg H1N1 Vaccine + saline placebo on Day 0; 15 mcg H1N1 Vaccine + saline placebo on Day 21, and Trivalent Influenza Vaccine (TIV) on Day 42", "Participants received 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 0; 15 mcg H1N1 Vaccine + saline placebo on Day 21, and saline placebo on Day 42", "Participants received 15 mcg H1N1 Vaccine + saline placebo on Day 0; 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 21, and saline placebo on Day 42", "Participants received 15 mcg H1N1 Vaccine + saline placebo on Day 0; 15 mcg H1N1 Vaccine + saline placebo on Day 21, and Trivalent Influenza Vaccine (TIV) on Day 42", "Total of all reporting groups"]], "pageTitle": "Sanofi H1N1 + TIV - Adults and Elderly - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00943878?sect=X7015&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 6, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988924.75/warc/CC-MAIN-20150728002308-00079-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 867016376, "recordOffset": 866999982, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were healthy adult males and females recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 7AUG2009 and 28AUG2009. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: Trivalent inactivated influenza vaccine Biological: Inactivated H1N1 Vaccine Drug: Placebo Interventions: Influenza Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type:", "textAfterTable": "\u00a0 \u00a0 Group 1: H1N1+Placebo; H1N1+Placebo; TIV \u00a0 \u00a0 Group 2: H1N1+TIV; H1N1+Placebo; Placebo \u00a0 \u00a0 Group 3: H1N1+Placebo; H1N1+TIV; Placebo \u00a0 \u00a0 Group 4: TIV+Placebo; H1N1+Placebo; H1N1 \u00a0 STARTED \u00a0 \u00a0 202 \u00a0 \u00a0 200 \u00a0 \u00a0 203 \u00a0 \u00a0 200 \u00a0 COMPLETED \u00a0 \u00a0 200 \u00a0 \u00a0 198 \u00a0 \u00a0 197 \u00a0 \u00a0 198 \u00a0 NOT COMPLETED \u00a0 \u00a0 2 \u00a0 \u00a0 2 \u00a0 \u00a0 6 \u00a0 \u00a0 2 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}